Dow Up1.33% Nasdaq Up1.33%

More On ALPMF

Quotes

Charts

News & Info

Company

Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials

  • Income Statement
  • Balance Sheet
  • Cash Flow

Astellas Pharma, Inc. (ALPMF)

-Other OTC
16.32 0.00(0.00%) Jun 28
ProfileGet Profile for:
Astellas Pharma, Inc.
2-5-1, Nihonbashi-Honcho
Chuo-ku
Tokyo, 103-8411
Japan - Map
Phone: 81 3 3244 3000
Website: http://www.astellas.com

Details 
Index Membership:N/A
Sector:N/A
Industry:N/A
Full Time Employees:17,217

Business Summary 

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on the therapeutic areas of urology, oncology, immunology, nephrology, neuroscience, muscle diseases, and ophthalmology. Its products include Prograf, an immunosuppressant to prevent rejection in organ transplants; Vesicare, a treatment for overactive bladder; Protopic, a treatment for atopic dermatitis in the topical immunomodulator class; Harnal, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard, a candin antifungal agent. The company also offers Geninax, an oral new-type quinolone antibacterial agent; Celecox, a COX-2 inhibitor; Lipitor, a treatment for hypercholesterolemia; Micardis, a treatment for hypertension; Gaster, a treatment for peptic ulcers and gastritis; Myslee, a hypnotic; Cefzon, an oral cephalosporin; Seroquel, an antipsychotic agent; Dorner, a treatment for chronic arterial occlusion; Nasea, a 5-HT3 receptor antagonist; Regnite, a treatment for restless legs syndrome; and Kiklin, a treatment for hyperphatemia. In addition, it provides Lexiscan, a pharmacologic stress agent; Adenoscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; Vaprisol, a treatment for euvolemic hyponatremia; AmBisome, a systemic antifungal agent; Eligard, a treatment for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt, a treatment for acne; Locobase, a treatment for dry skin; and Dificlir, a novel treatment for CDI. The company has a collaboration with Chromocell Corporation to develop and commercialize treatments for neuropathic pain and other pain conditions; and collaborative research agreement with the National Institute of Advanced Industrial Science and Technology to discover anti-protozoan parasite drugs for the treatment of Chagas' disease. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Astellas Pharma, Inc.

Key Executives 
 PayExercised
Mr. Yoshihiko Hatanaka ,
Chief Exec. Officer, Pres and Representative Director
2.06MN/A
Mr. Yoshiro Miyokawa ,
Chief Admin. Officer, Chief Compliance Officer, Exec. VP, Representative Director, Chairman of Global Compliance Committee and Member of Compensation Committee
1.03MN/A
Mr. Eugene Van Rensburg ,
Chief Financial Officer
N/AN/A
Mr. Percival Barretto-Ko ,
Sr. VP of International Operations
N/AN/A
Chikashi Takeda ,
Corp. Exec. and Corp. VP of Corp. Fin. & Control
N/AN/A
Amounts are as of Dec 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.